Structural Comparative Modeling of Multi-Domain F508del CFTR

被引:10
|
作者
McDonald, Eli Fritz [1 ,2 ]
Woods, Hope [2 ,3 ]
Smith, Shannon T. [2 ,3 ]
Kim, Minsoo [3 ]
Schoeder, Clara T. [1 ,2 ,4 ]
Plate, Lars [1 ,5 ]
Meiler, Jens [1 ,2 ,4 ,6 ,7 ]
机构
[1] Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA
[2] Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37235 USA
[3] Vanderbilt Univ, Program Chem & Phys Biol, Nashville, TN 37235 USA
[4] Univ Leipzig, Leipzig Med Sch, D-04109 Leipzig, Germany
[5] Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37235 USA
[6] Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37235 USA
[7] Univ Leipzig, Inst Drug Discovery, D-04109 Leipzig, Germany
关键词
cystic fibrosis; comparative modeling; computational protein modeling; protein folding disease; pharmacological chaperones; VX-809; structure-based drug discovery; TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-BINDING DOMAIN; CORRECTOR VX-809; LIGAND DOCKING; MUTATION; NBD1; PREDICTION; MECHANISM; IDENTIFICATION; SIMULATIONS;
D O I
10.3390/biom12030471
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cystic fibrosis (CF) is a rare genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), an epithelial anion channel expressed in several vital organs. Absence of functional CFTR results in imbalanced osmotic equilibrium and subsequent mucus build up in the lungs-which increases the risk of infection and eventually causes death. CFTR is an ATP-binding cassette (ABC) transporter family protein composed of two transmembrane domains (TMDs), two nucleotide binding domains (NBDs), and an unstructured regulatory domain. The most prevalent patient mutation is the deletion of F508 (F508del), making F508del CFTR the primary target for current FDA approved CF therapies. However, no experimental multi-domain F508del CFTR structure has been determined and few studies have modeled F508del using multi-domain WT CFTR structures. Here, we used cryo-EM density data and Rosetta comparative modeling (RosettaCM) to compare a F508del model with published experimental data on CFTR NBD1 thermodynamics. We then apply this modeling method to generate multi-domain WT and F508del CFTR structural models. These models demonstrate the destabilizing effects of F508del on NBD1 and the NBD1/TMD interface in both the inactive and active conformation of CFTR. Furthermore, we modeled F508del/R1070W and F508del bound to the CFTR corrector VX-809. Our models reveal the stabilizing effects of VX-809 on multi-domain models of F508del CFTR and pave the way for rational design of additional drugs that target F508del CFTR for treatment of CF.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] MODULATING THE DYNAMICS OF RIBOSOME FUNCTION RESCUES F508DEL CFTR MATURATIONAL ARREST
    Oliver, K. E.
    Veit, G.
    Icyuz, M.
    Guo, J.
    McClure, M. L.
    Hong, J. S.
    Wen, H.
    Sorscher, E. J.
    Lukacs, G. L.
    Hartman, J. L.
    PEDIATRIC PULMONOLOGY, 2014, 49 : 217 - 217
  • [32] ELECTROCHEMICAL MEMBRANE CHOLESTEROL MEASUREMENT AS A BIOMARKER FOR PHARMACOLOGICAL F508DEL CFTR CORRECTION
    Lu, B.
    Corey, D.
    Hodges, C. A.
    Cotton, C.
    Kelley, T.
    PEDIATRIC PULMONOLOGY, 2019, 54 : S362 - S362
  • [33] ANALYSIS OF THE THERMAL UNFOLDING OF CFTR NUCLEOTIDE BINDING DOMAIN 1 SUGGESTS A MECHANISM FOR THE TRAFFICKING DEFECT AND TEMPERATURE RESCUE OF (F508DEL) CFTR
    Protasevich, I
    Yang, Z.
    Wang, C.
    Atwell, S.
    Zhao, X.
    Emtage, S.
    Wetmore, D.
    Hunt, J. F.
    Brouillette, C.
    PEDIATRIC PULMONOLOGY, 2010, : 233 - 233
  • [34] The novel CFTR haplotype E583G/F508del in CFTR-related disorder
    De Paolis, Elisa
    Tilocca, Bruno
    Inchingolo, Riccardo
    Lombardi, Carla
    Perrucci, Alessia
    Maneri, Giulia
    Roncada, Paola
    Varone, Francesco
    Luca, Richeldi
    Urbani, Andrea
    Minucci, Angelo
    Santonocito, Concetta
    MOLECULAR BIOLOGY REPORTS, 2024, 51 (01)
  • [35] STRUCTURAL DEFECT TARGETED SCREENING ASSAYS LEAD TO THE PHARMACOLOGICAL DISSECTION OF CFTR MISFOLDING AND IMPROVED F508DEL CORRECTION
    Liang, F.
    Shang, H.
    Jordan, N. J.
    Wong, E.
    Veit, G.
    Lukacs, G. L.
    Bihler, H. J.
    Mense, M.
    PEDIATRIC PULMONOLOGY, 2014, 49 : 217 - 217
  • [36] Calumenin contributes to ER-Ca2+ homeostasis in bronchial epithelial cells expressing WT and F508del mutated CFTR and to F508del-CFTR retention
    Philippe, Reginald
    Antigny, Fabrice
    Buscaglia, Paul
    Norez, Caroline
    Huguet, Florentin
    Castelbou, Cyril
    Trouve, Pascal
    Becq, Frederic
    Frieden, Maud
    Ferec, Claude
    Mignen, Olivier
    CELL CALCIUM, 2017, 62 : 47 - 59
  • [37] CHANGE IN BURDEN OF ILLNESS IN CF PATIENTS HOMOZYGOUS FOR THE F508DEL CFTR GENE MUTATION
    Lubarsky, B.
    O'Sullivan, A.
    Millar, S.
    Pasta, D.
    Sawicki, G.
    Wagener, J.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 346 - 347
  • [38] CHANGES IN LCI IN F508DEL/F508DEL PATIENTS TREATED WITH LUMACAFTOR/IVACAFTOR: RESULTS FROM THE PROSPECT STUDY
    Ratjen, F.
    Klingel, M.
    Clancy, J. P.
    Sagel, S.
    Donaldson, S. H.
    Rowe, S. M.
    PEDIATRIC PULMONOLOGY, 2017, 52 : S287 - S287
  • [39] EFFECTS OF LUMACAFTOR/IVACAFTOR IN CYSTIC FIBROSIS PATIENTS HOMOZYGOUS FOR F508DEL CFTR MUTATION
    Melotti, P.
    Tridello, G.
    Pintani, E.
    Meneghelli, I
    Volpi, S.
    Spinelli, E.
    D'Orazio, C.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 242 - 242
  • [40] F508DEL IMPAIRMENT OF NBD DIMERIZATION
    Chong, P.
    Hudson, R.
    Vernon, R. M.
    Forman-Kay, J.
    PEDIATRIC PULMONOLOGY, 2013, 48 : 228 - 228